Ocular Therapeutix Nasdocul
2 known investors
Ocular is a clinical-stage biopharmaceutical company developing AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel, aimed at reducing the treatment burden of retinal diseases. Its lead therapy is in Phase 3 clinical trials for wet AMD, with additional focus on diabetic retinopathy.
BiotechHealthtechMedical Devices
Investors Β· 2
Frequently asked questions
- What does Ocular Therapeutix Nasdocul do?
- Ocular is a clinical-stage biopharmaceutical company developing AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel, aimed at reducing the treatment burden of retinal diseases. Its lead therapy is in Phase 3 clinical trials for wet AMD, with additional focus on diabetic retinopathy.
- Who are Ocular Therapeutix Nasdocul's investors?
- Ocular Therapeutix Nasdocul's investors include Ascension Ventures, Top Corner Capital.